Results 41 to 50 of about 853 (171)

Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]

F1000Research, 2022
Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs, Panagiotis Zagaliotis, Thomas J. Walsh   +2 more
doaj   +1 more source

EUCAST olorofim MICs for 3,550 Danish mold and dermatophyte isolates from 2020 to 2023. [PDF]

Antimicrob Agents Chemother
ABSTRACT The dihydroorotate dehydrogenase (DHODH) inhibitor olorofim has potent activity against most molds. Recent reports of in vitro acquired resistance to olorofim and an agrochemical fungicide DHODH inhibitor warrant continuous monitoring of in vitro
Meletiadis J, Jørgensen KM, Astvad KMT, Abou-Chakra N, Arendrup MC.   +4 more
europepmc   +4 more sources

EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data.
Jørgensen, Karin Meinike, Astvad, Karen M.T., Hare, Rasmus Krøger, Arendrup, Maiken Cavling   +3 more
openaire   +3 more sources

WITHDRAWN: Reversing olorofim activity reveals multifactorial drug tolerance in Aspergillus fumigatus

, 2023
Withdrawal StatementThe authors have withdrawn their manuscript owing to finding new evidence contradictory to the results and conclusions presented in this work. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Clara Valero, Myles Mcmanus, Ashva Ram Anna Durai, James Tindale, Sara Gago, Michael J Bromley   +5 more
openaire   +1 more source

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Olorofim (formerly F901318) is an advanced analog of the orotomide class that inhibits fungal pyrimidine biosynthesis. We evaluated the in vitro and in vivo activities of olorofim against Coccidioides species.
Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Michael Birch, Derek Law, John H. Rex, Gabriel Catano, Thomas F. Patterson   +8 more
openaire   +2 more sources

Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans

Journal of Antimicrobial Chemotherapy, 2020
Abstract Objectives Patients with immunodeficiency or cystic fibrosis frequently suffer from respiratory fungal infections. In particular, biofilm-associated fungi cause refractory infection manifestations, linked to increased resistance to anti-infective agents.
Joerg Steinmann, Peter-Michael Rath, Jan Buer, Ann-Kathrin Weisner, Silke Dittmer, Lisa Kirchhoff   +5 more
openaire   +3 more sources

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope [PDF]

, 2019
Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in immunocompromised and occasionally in healthy hosts. Scedosporium spp. is intrinsically resistant to most, L. prolificans to all the antifungal drugs currently
Aurbach U., Caggiano G., Chander J., Chedotal I., Cheng M. P., Cornely O. A., Denis J., Duarte R. F., Duran Graeff L., Hamprecht A., Herbrecht R., Kohler P., Lackner M., Los-Arcos I., Mares M., Meissner A., Mellinghoff S., Montagna M. T., Pakstis D. L., Piepenbrock E., Salmanton-Garcia J., Seidel D., Slavin M., Stecher M., Trauth J., Vehreschild J. J., Vehreschild M. J. G. T., Wisplinghoff H.   +27 more
core   +3 more sources

Antifungal metabolites, their novel sources, and targets to combat drug resistance [PDF]

, 2022
Excessive antibiotic prescriptions as well as their misuse in agriculture are the main causes of antimicrobial resistance which poses a growing threat to public health. It necessitates the search for novel chemicals to combat drug resistance.
Choudhary, Megha, Gupta, Sanjay, Kumar, Vijay, Kumar, Vivek, Naik, Bindu, Saris, Per Erik Joakim, Verma, Ankit   +6 more
core   +1 more source

Hope on the horizon: Novel fungal treatments in development [PDF]

, 2020
The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella, Larson, Lindsey, Rauseo, Adriana M, Spec, Andrej   +3 more
core   +1 more source

Advances in the Treatment of Invasive Fungal Disease [PDF]

, 2023
With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang, Bills, Gerald F, Zhang, Zhuan   +2 more
core   +1 more source